Health Economics›Cholangiocarcinoma›Metastatic disease subsequent lines of therapy

Metastatic disease subsequent lines of therapy

Cholangiocarcinoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #06	—	R 307 423	28d	~2.2 mo	~9.4 mo	~3	~R 922 268 PFS proxy · indirect	11
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~16.5 mo	~13.9 mo	~36	~R 10 330 390 PFS proxy · indirect	7
Lenvatinib and Pembrolizumab Variant #01	—	R 128 546	21d	~23.9 mo	~18.3 mo	~35	~R 4 499 104 PFS proxy · indirect	4
Capecitabine monotherapy Variant #17	—	R 2 219	21d	~5.7 mo	~7.5 mo	~9	~R 19 974 PFS proxy · indirect	11
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~1.8 mo	~10.9 mo	~4	—	6
Infigratinib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Pemigatinib monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Ivosidenib monotherapy Variant #01 Partial	—	—	28d	2.7 mo	—	3	—	1
Futibatinib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

9 of 9 regimens shown